ClinicalTrials.gg
CompletedNCT06862791ASCENDUpdated Jun 3, 2026

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Phase 2 interventional study of AZD9550 and AZD6234 in Obesity or Overweight, sponsored by AstraZeneca. Completed at 53 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.

Enrollment
Largest of 10
377 · median 85
Started
2025
with 4 others
Phase 2
4 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
10 of 10
AstraZeneca

Among the 10 studies testing AZD6234 in Obesity, this one has the largest enrollment, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About AZD6234

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing AZD6234 in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Read the detailed description

This is a Phase IIb, global, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, reduced factorial study designed to evaluate the efficacy, safety and tolerability of treatment with AZD9550 and AZD6234 in combination or as monotherapy in adults who are living with obesity or overweight with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia or obstructive sleep apnoea. The study is composed of a screening period, a treatment period and a follow up period with participants expected to be in the study for approximately 47 weeks. The study will be conducted at around 60 sites and in approximately 7 countries with about, 360 participants will be randomly assigned to study intervention or placebo.

03

Conditions studied

  • Obesity or Overweight

Keywords

  • Obesity
  • Overweight
  • AZD9550
  • AZD6234
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 75 years of age inclusive.
  • : ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.
  • A stable, self-reported body weight for 3 months prior to screening.
  • Male and female participants: use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
  • History or presence of GI, renal, hepatic disease.
  • Previous or planned bariatric surgery or fitting of a weight loss device.
  • Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
  • History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
  • ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
  • Significant gastric and hepatobiliary disease.
  • History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × at screening.
  • History of psychosis or bipolar disorder.
  • History of major depressive disorder within the 2 years prior to screening or depression.
  • Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.
  • Vulnerable populations
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Arm 1

    AZD9550 low dose + AZD6234 low dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 2

    AZD9550 medium dose + AZD6234 medium dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 3

    AZD9550 high dose + AZD6234 high dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 4

    AZD9550 low dose + AZD6234 medium dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 5

    AZD9550 medium dose + AZD6234 low dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 6

    AZD9550 high dose + AZD6234 medium dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 7

    AZD9550 medium dose + AZD6234 high dose or placebos

    Drug: AZD9550 · Drug: AZD6234 · Drug: Placebo comparator

  • Experimental
    Arm 8

    AZD9550 high dose or placebo

    Drug: AZD9550 · Drug: Placebo comparator

  • Experimental
    Arm 9

    AZD6234 high dose or placebo

    Drug: AZD6234 · Drug: Placebo comparator

Interventions

  • IMP injected subcutaneous, once weekly. Unit dose strength as per CSP

  • IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.

  • DrugPlacebo comparator

    Placebo matching IMP dose injected subcutaneously, once weekly.

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline after 36 weeks of treatment

    To determine whether treatment with AZD9550 and AZD6234 in combination is superior to placebo for weight loss

    Time frame: 36 weeks

  2. Weight loss ≥ 5% from baseline after 36 weeks of treatment

    To assess the effect of treatment with AZD9550 and AZD6234 in combination vs placebo on the proportion of participants with weight loss ≥ 5%

    Time frame: 36 weeks

Secondary outcomes

  1. Absolute change in body weight from baseline after 36 weeks of treatment

    To determine whether treatment with AZD9550 and AZD6234 in combination is superior to placebo for weight loss

    Time frame: 36 weeks

  2. Absolute change in body weight from baseline after 36 weeks of treatment

    To determine whether treatment with AZD9550 and AZD6234 in combination is superior to AZD9550 and AZD6234 monotherapy, and whether AZD9550 and AZD6234 as monotherapies are superior to placebo for weight loss

    Time frame: 36 weeks

  3. Weight loss ≥ 5% from baseline after 36 weeks of treatment

    To assess the effect of treatment with AZD9550 and AZD6234 in combination vs monotherapy, and assess the effect of AZD9550 and AZD6234 as monotherapies vs placebo, on the proportion of participants with weight loss ≥ 5%

    Time frame: 36 weeks

  4. Weight loss ≥ 10% and ≥ 15% from baseline after 36 weeks of treatment

    To assess the effect of treatment with AZD9550 and AZD6234 in combination vs placebo and monotherapy, and assess the effect of AZD9550 and AZD6234 as monotherapies vs placebo, on the proportion of participants with weight loss ≥ 10% and ≥ 15%

    Time frame: 36 weeks

  5. Prevalence of ADAs to AZD9550 and AZD6234 in combination and as monotherapies after 36 weeks of treatment

    To assess the immunogenicity profile of treatment with AZD9550 and AZD6234 in combination and as monotherapies

    Time frame: 36 weeks

  6. Incidence of ADAs to AZD9550 and AZD6234 in combination and as monotherapies after 36 weeks of treatment

    To assess immunogenicity profile of ADAs to AZD9550 and AZD6234 in combination and as monotherapies

    Time frame: 36 weeks

  7. Titres of ADAs to AZD9550 and AZD6234 in combination and as monotherapies after 36 weeks of treatment

    To assess the immunogenicity profile of treatment with AZD9550 and AZD6234 in combination and as monotherapies

    Time frame: 36 weeks

  8. Percent change in body weight from baseline after 36 weeks of treatment

    To determine whether treatment with AZD9550 and AZD6234 in combination is superior to AZD9550 and AZD6234 monotherapy, and whether AZD9550 and AZD6234 as monotherapies are superior to placebo for weight loss

    Time frame: 36 weeks

07

Study locations

53 sites
  • Research Site
    Dothan, Alabama 36305, United States
  • Research Site
    Vestavia Hills, Alabama 35216, United States
  • Research Site
    Cerritos, California 90703, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Sacramento, California 95864, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Stockbridge, Georgia 30281, United States
  • Research Site
    Champaign, Illinois 61822, United States
  • Research Site
    South Bend, Indiana 46617, United States
  • Research Site
    Valparaiso, Indiana 46383, United States
  • Research Site
    Sioux City, Iowa 51106, United States
  • Research Site
    Southfield, Michigan 48034, United States
  • Research Site
    Missoula, Montana 59804, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Albuquerque, New Mexico 87107, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Tulsa, Oklahoma 74133, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Brownsville, Texas 78526, United States
  • Research Site
    Houston, Texas 77043, United States
  • Research Site
    Arlington, Virginia 22206, United States
  • Research Site
    Renton, Washington 98057, United States
  • Research Site
    Maroochydore, 4556, Australia
  • Research Site
    Maroubra, 2035, Australia
  • Research Site
    Norwood, 5067, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Calgary, Alberta T2V 4J2, Canada
  • Research Site
    Surrey, British Columbia V3T 4G8, Canada
  • Research Site
    Guelph, Ontario N1G 0B4, Canada
  • Research Site
    Hamilton, Ontario L8J 0B6, Canada
  • Research Site
    Hamilton, Ontario L8L 5G8, Canada
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
  • Research Site
    Stouffville, Ontario L4A1H2, Canada
  • Research Site
    Montreal, Quebec H4N 2W2, Canada
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Falkensee, 14612, Germany
  • Research Site
    Hamburg, 22607, Germany
  • Research Site
    Münster, 48145, Germany
  • Research Site
    Oldenburg, 23758, Germany
  • Research Site
    Chūōku, 103-0027, Japan
  • Research Site
    Chūōku, 104-0031, Japan
  • Research Site
    Fukuoka, 812-0025, Japan
  • Research Site
    Shinjuku-ku, 160-0008, Japan
  • Research Site
    Suita-shi, 565-0853, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2026, 14 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Mar 6, 2025
StartActual
Feb 18, 2025
Primary completionActual
May 11, 2026
CompletionActual
May 11, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06862791
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Feb 18, 2025
Primary completion
May 11, 2026
Completion
May 11, 2026
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9550 · AZD6234

Start the discussion